Home / Market News / $ARGX
benzinga Corporate Catalyst Impact 85/100 ● negative

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Oct 8, 2026, 12:07 PM UTC · Primary ticker $ARGX

Argenx announced the discontinuation of its Phase 3 UNITY study for efgartigimod in Sjögren's disease due to futility, as recommended by the IDMC. This news led to a sharp decline in Argenx's pre-market shares and contributed to a broader negative sentiment across several other stocks mentioned in the filing.

Argenx's decision to discontinue its Phase 3 UNITY study for efgartigimod in Sjögren's disease is a significant negative catalyst for the company. The recommendation by the IDMC for futility indicates that the drug was unlikely to meet its primary endpoints, representing a setback in its pipeline and potential future revenue streams. This directly impacts Argenx's stock, leading to an 8.7% dip in pre-market trading. For traders, this presents a short-term selling opportunity for ARGX and potentially a long-term re-evaluation of its pipeline. The broader market decline, with Dow futures falling, suggests a general risk-off sentiment, which exacerbates the negative impact on other stocks mentioned, especially those in the biotech sector like Immunovant, which also reported negative trial results.

$ARGX negative Phase 3 study discontinued due to futility
$IMVT negative Proof-of-concept trial missed primary endpoint
$PHR negative General market downturn/unspecified
$ZVRA negative General market downturn/unspecified
$CRBU negative General market downturn/unspecified
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.